Sitagliptin Versus Ipragliflozin for Type 2 Diabetes in Clinical Practice

Background: null Dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter-2 inhibitors are frequently used to treat type 2 diabetes. However, there have been no direct comparisons of these antidiabetic drugs in Japanese patients with type 2 diabetes. null null null null null null Methods: null We retrospectively assessed the effects of treatment with sitagliptin (a dipeptidyl peptidase-4 inhibitor) for 24 weeks in the ASSET-K study or...